Understanding why CAR T cells don't last in leukemia treatment
Determining the Mechanisms of Loss of CAR T Cell Persistence
University College, London · NCT05809284
This study looks at kids and young adults with leukemia to see why CAR T cells don't stick around long enough after treatment and what might help them last longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | N/A to 25 Years |
| Sex | All |
| Sponsor | University College, London (other) |
| Drugs / interventions | CAR-T, CAR T, chimeric antigen receptor |
| Locations | 3 sites (London and 2 other locations) |
| Trial ID | NCT05809284 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on pediatric and young adult patients with acute lymphoblastic leukemia (ALL) who are set to receive CD19-targeted CAR T-cell therapy. It aims to investigate the persistence of CAR T cells over time and identify the factors that may influence their longevity. By monitoring these patients, researchers hope to gather valuable data that can inform future treatments and improve outcomes for ALL patients.
Who should consider this trial
Good fit: Ideal candidates are children and young adults aged 25 years or younger with relapsed or refractory acute lymphoblastic leukemia who are scheduled to receive CAR T-cell treatment.
Not a fit: Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved CAR T cell therapies that enhance treatment effectiveness for leukemia patients.
How similar studies have performed: While this study explores a specific aspect of CAR T cell therapy, similar studies have shown promise in understanding CAR T cell dynamics and improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel) 2. Written informed consent Exclusion Criteria: 1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial 2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol
Where this trial is running
London and 2 other locations
- Great Ormond Street Hospital — London, United Kingdom (RECRUITING)
- University College London Hospital — London, United Kingdom (RECRUITING)
- Royal Manchester Children's Hospital — Manchester, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: CARPERS Trial Manager
- Email: ctc.carpers@ucl.ac.uk
- Phone: 442031084189
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, in Relapse